FDA-cleared leadership Neuro20 has FDA clearance for the Neuro20 PRO System, establishing credibility and a strong value proposition for medical facilities. Targeted outreach to hospitals, rehabilitation centers, and clinics seeking compliant EMS solutions could accelerate enterprise pilots and larger-scale deployments.

Strategic partnerships Recent collaboration with The Walk Foundation signals a willingness to form alliances to drive clinical validation and accessibility. Leverage partnership angles to propose joint validation studies, sponsor-backed pilots, and co-marketed programs with rehab networks and patient advocacy groups.

Niche rehabilitation focus The WB-EMS suit and software target musculoskeletal injuries, neuromuscular disease, and performance training, offering a unique blend of diagnostics-to-interventions. Market opportunities exist in clinics expanding neuromuscular rehab capabilities and sports performance facilities seeking innovative, evidence-based therapies.

Global SaaS / hardware stack A combined software platform with a washable, wearable EMS suit enables scalable deployment across clinics and group sessions. Propose enterprise licenses, managed services, and training packages to fitness studios, physical therapy chains, and corporate wellness programs seeking scalable EMS programs.

Revenue growth signals With reported revenue in the low-to-mid millions and a lean team, Neuro20 is positioned for nimble pilot programs and rapid expansion. Focus on high-velocity deals, contract manufacturing partnerships, and regional distributors to convert pilots into multi-site deployments.